A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PtGA / patient global assessment of disease activity

[Related PubMed/MEDLINE]
Total Number of Papers: 23
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PtGA  (>> Co-occurring Abbreviation)
Long Form:   patient global assessment of disease activity
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study. DAPSA, FM, HAQ-DI, MDA, PsA, PsAID, SCC
2020 Outcome Measures in Large Vessel Vasculitis: Relationship Between Patient-, Physician-, Imaging-, and Laboratory-Based Assessments. CRP, ESR, GCA, PhGA, SF-36, TAK
2019 Development and Validation of an 18 F-Fluorodeoxyglucose-Positron Emission Tomography With Computed Tomography-Based Tool for the Evaluation of Joint Counts and Disease Activity in Patients With Rheumatoid Arthritis. 18F-FDG, CT, DAS, DAS28-ESR, PET, RA, SJC, TJC
2019 Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. ASQoL, BP, EQ-5D-3L, FACIT-Fatigue, PCS, PF, PGJS, PROs, PsA, RP, SF, SF-36v2, TNFi-IR
2019 Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. bDMARD-IR, HAQ-DI, ISI, MCID, NNT, PCS, PROs, RA, SF-36
2019 Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. ADA, MTX, PROs, RA
2019 Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. ASQoL, BP, csDMARD-IR, EQ-5D-3L, FACIT-Fatigue, PCS, PF, PGJS, PROs, PsA, SF-36v2
2019 Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. FACIT-F, HAQ-DI, LSM, MCIDs, NNT, PROs, SF-36
2018 Determinants of Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity in patients with rheumatoid arthritis: A post hoc analysis of overall and Japanese results from phase 3 clinical trials. PhGA, RA, SJC28, TJC28, VAS
10  2018 Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. FACIT-F, HAQ-DI, LSM, MCID, MCS, PCS, PROs, RA, RAID, VASs
11  2018 Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial. csDMARDs, FACIT-F, HAQ-DI, PGA, RA, SF-36, WLQ
12  2018 [Clinical therapeutic effects on rheumatoid arthritis treated with the assisted therapy of acupuncture at the points detected with thermosensitive moxibustion in Zhuang medicine]. A-CCP, CRP, DAS28, ESR, EULAR, RA, RF, SJC 28, TJC 28
13  2017 Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. EQ-5D, FACIT-F, HAQ-DI, MJS, MTX, PROs, WPAI-RA
14  2017 Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. FACIT-F, HAQ-DI, MJS, PROs, RA, VAS
15  2017 Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). bDMARDs, FACIT-F, HAQ-DI, MJS, PROs, RA-BEACON, TNFis
16  2017 Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. ANCOVA, DMARDs, EQ-5D, FACIT-F, HAQ-DI, MJS, MTX, PROs, RA, SF-36, WPAI-RA
17  2016 Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. FACIT-F, HAQ-DI, MCID, PROs, RA, RCT, SF-36
18  2015 Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. DMARD-IR, FACIT-F, HAQ-DI, IVRS, MOS, PROs, SF-36
19  2015 Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. CZP, MCID, PROs, RA, RADAI, RAPID3
20  2015 Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial. DI, FACIT-F, HAQ, MOS, PROs, RA, TNFi
21  2014 Real-life treatment profile of calcipotriene and betamethasone dipropionate topical suspension in patients with psoriasis vulgaris. AEs, CBD, DLQI, PROs, TSQM-9
22  2012 Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. HAQ-DI, HRQoL, MCID, PCS, SF-36
23  2011 Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. CZP, MCIDs, MTX, NNT, PROs, RA